timothy sykes logo
REPL Stock Crashes As FDA Rejects RP1 Melanoma Bid Again Thumbnail
G Google News

REPL Stock Crashes As FDA Rejects RP1 Melanoma Bid Again

BRYCE TUOHEY•UPDATED APR. 26, 2026, 10:05 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Replimune Group Inc. stocks have been trading down by -15.79 percent following negative sentiment from its latest clinical trial update.

Candlestick Chart

Weekly Update Apr 20 – Apr 24, 2026: On Sunday, April 26, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending down by -15.79%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

Replimune (REPL) now sits as a distressed small-cap oncology platform with a broken lead asset. Fundamentals reflect a classic binary biotech unwind: negative ROE (~-91%) and ROA (~-67%), deeply loss-making EBITDA of -$67.6M for the quarter, and heavy R&D at $53.1M versus zero product revenue. However, the balance sheet is still solid near term: cash and short-term investments of ~$269M, working capital of ~$230M, current ratio 5.6x, total-debt-to-equity 0.36x, and enterprise value only about $7M, implying the market is valuing the pipeline close to liquidation levels.

Technically, the stock is in a sharp downtrend with oversold stabilization attempts. Weekly data show a rebound from $1.83 to a spike high at $2.88 before fading to $2.40, indicating short-covering plus speculative trading after the FDA setback. Intraday 5-minute candles have shown heavy volume around $2.20–$2.50, with repeated rejections into the high $2s. The dominant trend remains down; an actionable level is $2.20: breakdown below that on volume favors short/avoid, while aggressive traders could trade bounces toward $2.80 with tight risk controls.

Catalysts are overwhelmingly negative: a second FDA Complete Response Letter for RP1, removal of melanoma upside from multiple banks’ models, across-the-board downgrades (several to Sell/Underweight), and class-action investigations. Sector-wise, REPL now trades far below Healthcare and Biotech benchmarks on EV/cash and risk-adjusted pipeline value, with no credible near-term regulatory path for its lead program. Base case is value destruction via restructuring or pipeline pivot. I see $1.50–$2.00 as likely support, $3.00 as strong resistance, and a 6–12 month fair value near $2 absent a credible new strategy.

Quick Financial Overview

Replimune Group Inc. has shifted from a development-stage growth story to a damaged, high-risk chart in a matter of days. The weekly data show REPL trading around the low $2 range, with a rebound from $1.83 to $2.85 before slipping back near $2.40. That pattern tells you volatility is extreme and bounces are being sold rather than built into new uptrends.

The intraday 5‑minute snapshot, with price fading from about $2.78 to $2.42, confirms this selling pressure. Every push higher is met with supply, which is what you expect after a 60%+ gap-down on heavy volume tied to the FDA’s second Complete Response Letter. For short-term traders, this is a broken chart where liquidity is available, but the trend is clearly down and sharp pops can reverse fast.

More Breaking News

On the fundamental side, Replimune Group Inc. is burning cash aggressively, with operating cash flow around -$65.96M in the recent quarter and free cash flow about -$66.09M. The balance sheet does show strength for now: cash and short-term investments near $269.14M, a current ratio of 5.6, and total debt to equity at 0.36. Still, returns are deeply negative, with return on equity worse than -90%, and valuation ratios like price-to-book near 0.95 reflect a market pricing REPL close to its accounting equity while heavily discounting future success.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading REPL

Millionaire's
POV on REPL

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”